Institutional members access full text with Ovid®

Share this article on:

Bacterial infections of the small intestine

Hodges, Kima; Hecht, Gaila,b

Current Opinion in Gastroenterology: March 2013 - Volume 29 - Issue 2 - p 159–163
doi: 10.1097/MOG.0b013e32835b422c
SMALL INTESTINE: Edited by David H. Alpers and William F. Stenson

Purpose of review The purpose of this study is to summarize the recent developments in small intestinal bacterial infections.

Recent findings This review focuses on aspects of intestinal bacterial infection concerning research developments related to pathogenesis, new therapeutic agents and approaches, as well as potential new vaccine targets.

Summary In terms of drug utilization, azithromycin was successfully used to eradicate a Shiga toxin producing Escherichia coli (enterohemorrhagic E. coli) without harmful effects. In the case of Clostridium difficile, fidaxomicin was found to be comparable to or superior to vancomycin depending on study conditions and whether there was concomitant antibiotic use. A novel research finding is the role of galectin 8, which is a danger-sensing lectin, which plays a role in targeting Salmonella for autophagy. In addition, several enteropathogenic E. coli and Shigella effectors were found to inactivate members of the nuclear factor kappa B pathway.

aDepartment of Digestive Disease and Nutrition, University of Illinois at Chicago

bJesse Brown VA, Chicago, Illinois, USA

Correspondence to Dr Gail Hecht, University of Illinois at Chicago, 738A Clinical Sciences Building, 840 S. Wood Street, Chicago, IL 60612, USA. Tel: +1 312 996 1565; fax: +1 312 996 5103; e-mail:

© 2013 Lippincott Williams & Wilkins, Inc.